Cardiology

ESC 2024: The SHAM-PVI trial confirms that catheter ablation significantly reduces atrial fibrillation burden and improves quality of life compared to a sham treatment.

ESC 2024: OCT-guided PCI in complex lesions reduced cardiac risks by 38% and spontaneous MI by 64% versus angiography, according to the OCCUPI trial.

Atrial fibrillation screening using a 14-day wearable heart monitor patch significantly increased diagnoses compared to usual care, according to research presented at ESC 2024.

The PROTEUS trial, presented at ESC 2024, evaluated the effectiveness of AI in standardizing clinician decision-making during stress echocardiography for coronary artery disease

Presented at ESC 2024, vutrisiran, an RNAi therapeutic, significantly reduced mortality and cardiovascular events in patients with ATTR-CM.

Integrating a polygenic score with clinical data improves predicting ascending aortic diameter and thoracic aortic events, outperforming traditional models.

Benzodiazepine usage has been associated with increased risk of coronary heart diseases heart failure, and cardiovascular death, according to recent research.

Researchers have determined that the benefit of bystander cardiopulmonary resuscitation on survival for out-of-hospital cardiac arrest is lowest in non-Hispanic Black individuals and women.